{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:27:14Z","timestamp":1790468834867,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,8,25]],"date-time":"2014-08-25T00:00:00Z","timestamp":1408924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,8,25]],"date-time":"2014-08-25T00:00:00Z","timestamp":1408924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1038\/leu.2014.251","type":"journal-article","created":{"date-parts":[[2014,8,25]],"date-time":"2014-08-25T06:38:07Z","timestamp":1408948687000},"page":"668-676","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":115,"title":["Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry Study"],"prefix":"10.1038","volume":"29","author":[{"given":"H R","family":"Junl\u00e9n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Kimby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Lockmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Lind\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Nilsson-Ehle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Erlanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Hagberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"R\u00e5dlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Hagberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B E","family":"Wahlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,25]]},"reference":[{"key":"BFleu2014251_CR1","first-page":"220","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"NL Harris","year":"2008","unstructured":"Harris NL, Swerdlow SH, Jaffe ES, Ott G, Nathwani D . Follicular lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon, France, 2008, pp 220\u2013226."},{"key":"BFleu2014251_CR2","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1038\/leu.2014.91","volume":"28","author":"W Hiddemann","year":"2014","unstructured":"Hiddemann W, Cheson BD . How we manage follicular lymphoma. Leukemia 2014; 28: 1388\u20131395.","journal-title":"Leukemia"},{"key":"BFleu2014251_CR3","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1158\/1541-7786.MCR-11-0154","volume":"9","author":"C Bezombes","year":"2011","unstructured":"Bezombes C, Fournie JJ, Laurent G . Direct effect of rituximab in B-cell-derived lymphoid neoplasias: mechanism, regulation, and perspectives. Mol Cancer Res 2011; 9: 1435\u20131442.","journal-title":"Mol Cancer Res"},{"key":"BFleu2014251_CR4","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825\u20132833.","journal-title":"J Clin Oncol"},{"key":"BFleu2014251_CR5","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","volume":"105","author":"R Marcus","year":"2005","unstructured":"Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417\u20131423.","journal-title":"Blood"},{"key":"BFleu2014251_CR6","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725\u20133732.","journal-title":"Blood"},{"key":"BFleu2014251_CR7","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","volume":"25","author":"M Herold","year":"2007","unstructured":"Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007; 25: 1986\u20131992.","journal-title":"J Clin Oncol"},{"key":"BFleu2014251_CR8","doi-asserted-by":"publisher","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","volume":"112","author":"G Salles","year":"2008","unstructured":"Salles G, Mounier N, de Guibert S, Morschhauser F, Doyen C, Rossi JF et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008; 112: 4824\u20134831.","journal-title":"Blood"},{"key":"BFleu2014251_CR9","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood.V95.10.3052","volume":"95","author":"JD Hainsworth","year":"2000","unstructured":"Hainsworth JD, Burris HA III, Morrissey LH, Litchy S, Scullin DC Jr Bearden JD III et al Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000; 95: 3052\u20133056.","journal-title":"Blood"},{"key":"BFleu2014251_CR10","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1182\/blood.V97.1.101","volume":"97","author":"P Colombat","year":"2001","unstructured":"Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 101\u2013106.","journal-title":"Blood"},{"key":"BFleu2014251_CR11","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","volume":"103","author":"M Ghielmini","year":"2004","unstructured":"Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x4 schedule. Blood 2004; 103: 4416\u20134423.","journal-title":"Blood"},{"key":"BFleu2014251_CR12","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1080\/10428190701704647","volume":"49","author":"E Kimby","year":"2008","unstructured":"Kimby E, Jurlander J, Geisler C, Hagberg H, Holte H, Lehtinen T et al. Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group. Leuk Lymphoma 2008; 49: 102\u2013112.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2014251_CR13","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1200\/JCO.1995.13.1.140","volume":"13","author":"PW Johnson","year":"1995","unstructured":"Johnson PW, Rohatiner AZ, Whelan JS, Price CG, Love S, Lim J et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995; 13: 140\u2013147.","journal-title":"J Clin Oncol"},{"key":"BFleu2014251_CR14","doi-asserted-by":"publisher","first-page":"8447","DOI":"10.1200\/JCO.2005.03.1674","volume":"23","author":"RI Fisher","year":"2005","unstructured":"Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP . New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005; 23: 8447\u20138452.","journal-title":"J Clin Oncol"},{"key":"BFleu2014251_CR15","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1200\/JCO.2005.03.3696","volume":"24","author":"Q Liu","year":"2006","unstructured":"Liu Q, Fayad L, Cabanillas F, Hagemeister FB, Ayers GD, Hess M et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas MD Anderson Cancer Center. J Clin Oncol 2006; 24: 1582\u20131589.","journal-title":"J Clin Oncol"},{"key":"BFleu2014251_CR16","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","volume":"122","author":"D Tan","year":"2013","unstructured":"Tan D, Horning SJ, Hoppe RT, Levy R, Rosenberg SA, Sigal BM et al. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood 2013; 122: 981\u2013987.","journal-title":"Blood"},{"key":"BFleu2014251_CR17","unstructured":"Nationellt kvalitetsregister f\u00f6r lymfom. Available at: http:\/\/www.cancercentrum.se\/sv\/INCA\/kvalitetsregister\/Blodcancer\/lymfom (last accessed 30 December 2013)."},{"key":"BFleu2014251_CR18","unstructured":"Svenska lymfomgruppen. Available at: http:\/\/www.swedishlymphoma.se (last accessed 30 December 2013)."},{"key":"BFleu2014251_CR19","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Celigny","year":"2004","unstructured":"Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R et al. Follicular lymphoma international prognostic index. Blood 2004; 104: 1258\u20131265.","journal-title":"Blood"},{"key":"BFleu2014251_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2214\/ajr.117.1.45","volume":"117","author":"J Vijungco","year":"1973","unstructured":"Vijungco J, Phillips R, Hendrickson FR, Millburn LF . Stage I and II non-Hodgkin's lymphoma. Results of regional radiation therapy. Am J Roentgenol Radium Ther Nucl Med 1973; 117: 45\u201349.","journal-title":"Am J Roentgenol Radium Ther Nucl Med"},{"key":"BFleu2014251_CR21","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","volume":"362","author":"KM Ardeshna","year":"2003","unstructured":"Ardeshna KM, Smith P, Norton A, Hancock BW, Hoskin PJ, MacLennan KA et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003; 362: 516\u2013522.","journal-title":"Lancet"},{"key":"BFleu2014251_CR22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/02841860151116286","volume":"40","author":"L Brandt","year":"2001","unstructured":"Brandt L, Kimby E, Nygren P, Glimelius B . A systematic overview of chemotherapy effects in indolent non-Hodgkin's lymphoma. Acta Oncol 2001; 40: 213\u2013223.","journal-title":"Acta Oncol"},{"key":"BFleu2014251_CR23","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","volume":"21","author":"HC Schouten","year":"2003","unstructured":"Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnson HE et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21: 3918\u20133927.","journal-title":"J Clin Oncol"},{"key":"BFleu2014251_CR24","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1200\/JCO.2001.19.3.727","volume":"19","author":"CD Williams","year":"2001","unstructured":"Williams CD, Harrison CN, Lister TA, Norton AJ, Blystad AK, Coiffier B et al. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol 2001; 19: 727\u2013735.","journal-title":"J Clin Oncol"},{"key":"BFleu2014251_CR25","doi-asserted-by":"publisher","first-page":"288","DOI":"10.3109\/10428194.2013.802778","volume":"55","author":"BE Wahlin","year":"2014","unstructured":"Wahlin BE, Sundstrom C, Sander B, Christensson B, Jeppsson-Ahlberg A, Hjalmarsson E et al. Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy. Leuk Lymphoma 2014; 55: 288\u2013295.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2014251_CR26","doi-asserted-by":"publisher","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","volume":"108","author":"MH van Oers","year":"2006","unstructured":"van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD et al. Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006; 108: 3295\u20133301.","journal-title":"Blood"},{"key":"BFleu2014251_CR27","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F, Lopez-Guillermo A, Belada D, Xerri L et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377: 42\u201351.","journal-title":"Lancet"},{"key":"BFleu2014251_CR28","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grunhagen U, Losem C et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203\u20131210.","journal-title":"Lancet"},{"key":"BFleu2014251_CR29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR . Regression models and life-tables. J R Stat Soc 1972; 34: 187\u2013220.","journal-title":"J R Stat Soc"},{"key":"BFleu2014251_CR30","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/1097-0142(19951115)76:10<1687::AID-CNCR2820761002>3.0.CO;2-I","volume":"76","author":"DE Henson","year":"1995","unstructured":"Henson DE, Ries LA . The relative survival rate. Cancer 1995; 76: 1687\u20131688.","journal-title":"Cancer"},{"key":"BFleu2014251_CR31","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1365-2796.2006.01677.x","volume":"260","author":"PW Dickman","year":"2006","unstructured":"Dickman PW, Adami HO . Interpreting trends in cancer patient survival. J Intern Med 2006; 260: 103\u2013117.","journal-title":"J Intern Med"},{"key":"BFleu2014251_CR32","volume-title":"Instructions to IBM 650 Programmers in Processing Survival Computations. Methodological Note No. 10, End Results Evaluation Section","author":"F Ederer","year":"1959","unstructured":"Ederer F, Heise H . Instructions to IBM 650 Programmers in Processing Survival Computations. Methodological Note No. 10, End Results Evaluation Section. National Cancer Institute: Bethesda, MD, USA, 1959."},{"key":"BFleu2014251_CR33","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1093\/biostatistics\/kxn021","volume":"10","author":"MP Perme","year":"2009","unstructured":"Perme MP, Henderson R, Stare J . An approach to estimation in relative survival regression. Biostatistics 2009; 10: 136\u2013146.","journal-title":"Biostatistics"},{"key":"BFleu2014251_CR34","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.3109\/10428191003743460","volume":"51","author":"A Conconi","year":"2010","unstructured":"Conconi A, Motta M, Bertoni F, Piona C, Stathis A, Wannesson L et al. Patterns of survival of follicular lymphomas at a single institution through three decades. Leuk Lymphoma 2010; 51: 1028\u20131034.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2014251_CR35","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/jnci\/djk152","volume":"99","author":"H Schulz","year":"2007","unstructured":"Schulz H, Bohlius JF, Trelle S, Skoetz N, Reiser M, Kober T et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007; 99: 706\u2013714.","journal-title":"J Natl Cancer Inst"},{"key":"BFleu2014251_CR36","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2169\/internalmedicine.45.1549","volume":"45","author":"N Tomita","year":"2006","unstructured":"Tomita N, Kodama F, Motomura S, Koharazawa H, Fujita H, Harano H et al. Prognostic factors in diffuse large B-cell lymphoma treated by risk-adopted therapy. Intern Med 2006; 45: 247\u2013252.","journal-title":"Intern Med"},{"key":"BFleu2014251_CR37","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1080\/10428190701809156","volume":"49","author":"L Ngo","year":"2008","unstructured":"Ngo L, Hee SW, Lim LC, Tao M, Quek R, Yap SP et al. Prognostic factors in patients with diffuse large B cell lymphoma: before and after the introduction of rituximab. Leuk Lymphoma 2008; 49: 462\u2013469.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2014251_CR38","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/j.1600-0609.2010.01541.x","volume":"86","author":"S Riihijarvi","year":"2011","unstructured":"Riihijarvi S, Taskinen M, Jerkeman M, Leppa S . Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy. Eur J Haematol 2011; 86: 124\u2013128.","journal-title":"Eur J Haematol"},{"key":"BFleu2014251_CR39","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1182\/blood-2014-03-559930","volume":"124","author":"A Abrahamsson","year":"2014","unstructured":"Abrahamsson A, Albertsson-Lindblad A, Brown PN, Baumgartner-Wennerholm S, Pedersen LM, D'Amore F et al. Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study. Blood 2014; 124: 1288\u20131295.","journal-title":"Blood"},{"key":"BFleu2014251_CR40","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3109\/10428194.2012.691482","volume":"54","author":"AM Carella","year":"2013","unstructured":"Carella AM, de Souza CA, Luminari S, Marcheselli L, Chiappella A, di Rocco A et al. Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi\/Grupo de Estudos em Molestias Onco-Hematologicas retrospective study. Leuk Lymphoma 2013; 54: 53\u201357.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2014251_CR41","doi-asserted-by":"publisher","first-page":"3276","DOI":"10.1182\/blood-2011-09-380949","volume":"119","author":"C Muller","year":"2012","unstructured":"Muller C, Murawski N, Wiesen MH, Held G, Poeschel V, Zeynalova S et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood 2012; 119: 3276\u20133284.","journal-title":"Blood"},{"key":"BFleu2014251_CR42","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1182\/blood-2013-07-517037","volume":"123","author":"M Pfreundschuh","year":"2014","unstructured":"Pfreundschuh M, Muller C, Zeynalova S, Kuhnt E, Wiesen MH, Held G et al. Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood 2014; 123: 640\u2013646.","journal-title":"Blood"},{"key":"BFleu2014251_CR43","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1200\/JCO.2001.19.8.2165","volume":"19","author":"SM O'Brien","year":"2001","unstructured":"O'Brien SM, Kantarjian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 2165\u20132170.","journal-title":"J Clin Oncol"},{"key":"BFleu2014251_CR44","unstructured":"Statistiska centra lbyr\u00e5n. Available at: http:\/\/www.scb.se (last accessed 1 August 2012)."},{"key":"BFleu2014251_CR45","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.1365-2141.2011.08942.x","volume":"156","author":"BE Wahlin","year":"2012","unstructured":"Wahlin BE, Yri OE, Kimby E, Holte H, Delabie J, Smeland EB et al. Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times. Br J Haematol 2012; 156: 225\u2013233.","journal-title":"Br J Haematol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2014251.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2014251","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2014251.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T21:27:59Z","timestamp":1717277279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2014251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,25]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["BFleu2014251"],"URL":"https:\/\/doi.org\/10.1038\/leu.2014.251","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,25]]},"assertion":[{"value":"17 July 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}